Vertex Pharmaceuticals Incorporated (FRA:VX1)
392.40
-6.75 (-1.69%)
At close: Jul 21, 2025, 10:00 PM CET
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.77B USD in the quarter ending March 31, 2025, with 2.96% growth. This brings the company's revenue in the last twelve months to $11.10B, up 8.98% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm)
$11.10B
Revenue Growth
+8.98%
P/S Ratio
9.79
Revenue / Employee
$1.82M
Employees
6,100
Market Cap
100.49B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.15B |
Siemens Aktiengesellschaft | 77.82B |
Deutsche Telekom AG | 120.25B |
Allianz SE | 109.03B |
Rheinmetall AG | 10.48B |
Siemens Energy AG | 37.44B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.84B |
Siemens Healthineers AG | 23.14B |
Vertex Pharmaceuticals News
- 3 days ago - Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today - Benzinga
- 7 days ago - Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis - Wallstreet:Online
- 7 days ago - Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire
- 7 days ago - Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain - Wallstreet:Online
- 7 days ago - Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain - Business Wire
- 8 days ago - Why Vertex Pharmaceuticals Continues To Outperfrom - Seeking Alpha
- 10 days ago - Vertex Pharmaceuticals's Options: A Look at What the Big Money is Thinking - Benzinga
- 12 days ago - Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch - Seeking Alpha